Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 14, 2019; 25(14): 1684-1696
Published online Apr 14, 2019. doi: 10.3748/wjg.v25.i14.1684
Published online Apr 14, 2019. doi: 10.3748/wjg.v25.i14.1684
Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
Min-Wei Yang, Xue-Liang Fu, Yong-Sheng Jiang, Ling-Ye Tao, Jian-Yu Yang, Yan-Miao Huo, Wei Liu, Jun-Feng Zhang, Rong Hua, Yong-Wei Sun, De-Jun Liu, Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Xiao-Jing Chen, Pei-Feng Liu, Central Laboratory, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Qiang Liu, Department of Pathology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Zhi-Gang Zhang, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University, Shanghai 200240, China
Author contributions: Liu DJ and Sun YW conceived and designed the experiments; Yang MW, Fu XL, Jiang YS, and Chen XJ performed the experiments and wrote the manuscript; Fu XL and Yang MW analyzed the data; Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, and Liu Q contributed clinical samples and data; Liu DJ, Sun YW, Zhang ZG, and Hua R revised and edited the manuscript; all authors reviewed and approved the final manuscript.
Supported by Municipal Commission of Health and Family Planning of Shanghai , China (No. 20174Y0243 to Liu DJ, No. 20154Y0163 to Chen XJ), Cultivating Funds of Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China (No. PYXJS 16-002 to Liu W).
Institutional review board statement: The research was approved by the Research Ethics Committee of Ren Ji Hospital.
Conflict-of-interest statement: No potential conflicts of interest are disclosed.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: De-Jun Liu, MAMS, Doctor, Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No 160, Pujian Road, Shanghai 200127, China. liudj1126@yeah.net
Telephone: +86-21-68383773 Fax: +86-21-68383699
Received: January 30, 2019
Peer-review started: January 31, 2019
First decision: February 26, 2019
Revised: March 5, 2019
Accepted: March 16, 2019
Article in press: March 16, 2019
Published online: April 14, 2019
Peer-review started: January 31, 2019
First decision: February 26, 2019
Revised: March 5, 2019
Accepted: March 16, 2019
Article in press: March 16, 2019
Published online: April 14, 2019
Core Tip
Core tip: This study for the first time demonstrated that programmed death ligand 1 (PD-L1) can be expressed by gastric neuroendocrine carcinoma (G-NEC) cancer cells and the high PD-L1 expression was associated with a poor prognosis. And the high expression of PD-L1 may be due to the copy number variation of PD-L1 gene or stimulation of tumor infiltrating lymphocytes. These findings provide important implications for the potential use of antibody therapies targeting the PD-1/PD-L1 signaling pathway in G-NECs.